Neurodegenerative Disease Market Report 2026

The neurodegenerative disease market size has grown strongly in recent years. It will grow from $57.23 billion in 2025 to $62.59 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to limited understanding of disease pathology, reliance on conventional symptomatic treatments, growing aging population, increasing healthcare infrastructure for neurology, limited availability of advanced diagnostic tools.

The neurodegenerative disease market size is expected to see strong growth in the next few years. It will grow to $88.5 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to advancements in gene and cell therapy, rising r&d in novel neuroprotective drugs, expansion of clinical trial networks, integration of ai for early diagnosis and patient monitoring, increasing adoption of personalized medicine approaches. Major trends in the forecast period include rising prevalence of neurodegenerative disorders, increasing investment in drug development and clinical trials, adoption of targeted and personalized therapies, growth in awareness and early diagnosis programs, expansion of home-based and outpatient care solutions.

The growing level of research activity and the rising number of clinical trials are expected to drive the growth of the neurodegenerative disease market in the coming years. Clinical trials are research investigations involving human participants that assess the safety, effectiveness, and potential side effects of new therapies, drugs, or medical devices. The increase in research and clinical trials is mainly driven by the expanding need for novel treatments to address evolving healthcare demands and improve patient outcomes. Clinical trials play a vital role in neurodegenerative disease research by generating essential evidence on the safety and efficacy of emerging therapies, thereby supporting therapeutic advancement and enhancing patient care. For instance, in December 2024, according to a report published by the Association of the British Pharmaceutical Industry (ABPI), a UK-based industry body, the number of UK industry-sponsored clinical trials initiated increased by 3.7% in 2023 compared to 2022. Therefore, the rise in research and clinical trials is contributing to the growth of the neurodegenerative disease market.

Major companies operating in the neurodegenerative disease market are concentrating on the development of innovative solutions, such as next-generation adaptive Deep Brain Stimulation (aDBS) systems, to improve treatment accuracy, enhance disease-modifying potential, and elevate patient quality of life. Next-generation adaptive deep brain stimulation (aDBS) systems are advanced neurostimulation technologies designed to deliver real-time, personalized therapy for Parkinson’s disease by continuously adjusting stimulation settings based on neural feedback, thereby optimizing therapeutic benefits and reducing side effects. For instance, in February 2025, Medtronic, a US-based medical technology company, obtained approval from the U.S. Food and Drug Administration (USFDA) for the world’s first adaptive deep brain stimulation (aDBS) system for Parkinson’s disease. This approval relates to the premarket approval (PMA) application for the Percept RC neurostimulator with BrainSense technology, which automatically modifies therapy in response to a patient’s brain signals. The system is clinically validated to provide symptom relief for patients with advanced Parkinson’s disease and represents a major advancement in personalized neuromodulation treatments.

In December 2024, AbbVie, a US-based biopharmaceutical company, acquired Aliada Therapeutics for an undisclosed amount. Through this acquisition, AbbVie aims to accelerate the development of potentially disease-modifying therapies for Alzheimer’s disease and reinforce its neuroscience pipeline by utilizing Aliada’s innovative drug delivery platform capable of crossing the blood-brain barrier. Aliada Therapeutics is a US-based company focused on developing precision medicines for neurological disorders.

Major companies operating in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.

North America was the largest region in the neurodegenerative disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurodegenerative disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurodegenerative disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the neurodegenerative disease market by increasing costs for imported active pharmaceutical ingredients, advanced diagnostic devices, and biotechnological equipment. Segments such as injectable therapies, gene-based treatments, and specialized diagnostic tools are particularly impacted, with regions like Europe, North America, and Asia-Pacific facing supply chain and price pressures. However, tariffs have also encouraged local manufacturing, domestic r&d investments, and the development of cost-efficient therapies, supporting long-term market resilience.

The neurodegenerative disease market research report is one of a series of new reports that provides neurodegenerative disease market statistics, including neurodegenerative disease industry global market size, regional shares, competitors with a neurodegenerative disease market share, detailed neurodegenerative disease market segments, market trends and opportunities, and any further data you may need to thrive in the neurodegenerative disease industry. This neurodegenerative disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurodegenerative disease refers to a category of disorders marked by the gradual deterioration of the structure and function of the nervous system, including the brain and spinal cord. This field focuses on understanding, diagnosing, and treating these conditions through advances in biotechnology, pharmaceuticals, and medical technologies. Its objectives include slowing disease progression, improving patient outcomes, and lowering the overall healthcare burden. It plays a key role in supporting aging populations, advancing neurological care, and promoting a sustainable, technology-driven healthcare system.

The major types of neurodegenerative diseases include Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington’s disease, and amyotrophic lateral sclerosis. Parkinson’s disease is a progressive neurological condition that impairs movement control due to the loss of dopamine-producing neurons in the brain. These disorders are managed using various drug classes, such as N-methyl-D-aspartate (NMDA) receptor antagonists, cholinesterase inhibitors, dopamine agonists, and immunomodulatory agents. Routes of administration include oral, injectable, transdermal, and other methods. These medications are distributed through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and other distribution outlets. The primary end users include hospitals, retail providers, and online platforms.

The neurodegenerative disease market consists of revenues earned by entities through services such as biotechnology research, pharmaceutical development, diagnostic solutions, medical technologies, and patient care advancements aimed at understanding, diagnosing, and treating neurodegenerative conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurodegenerative disease market also includes sales of pharmaceuticals, biotechnology treatments, medical devices, and diagnostic tools aimed at managing and treating neurodegenerative conditions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.